- Home
- GMM vs PDSB Comparison
GMM vs PDSB Comparison
Compare GMM & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- PDSB
- Stock Information
- Founded
- GMM 2017
- PDSB 2005
- Country
- GMM China
- PDSB United States
- Employees
- GMM N/A
- PDSB N/A
- Industry
- GMM
- PDSB Biotechnology: Pharmaceutical Preparations
- Sector
- GMM
- PDSB Health Care
- Exchange
- GMM Nasdaq
- PDSB Nasdaq
- Market Cap
- GMM 61.9M
- PDSB 54.5M
- IPO Year
- GMM 2023
- PDSB N/A
- Fundamental
- Price
- GMM $2.03
- PDSB $1.15
- Analyst Decision
- GMM
- PDSB Strong Buy
- Analyst Count
- GMM 0
- PDSB 2
- Target Price
- GMM N/A
- PDSB $10.00
- AVG Volume (30 Days)
- GMM 667.3K
- PDSB 642.8K
- Earning Date
- GMM 08-18-2025
- PDSB 11-13-2025
- Dividend Yield
- GMM N/A
- PDSB N/A
- EPS Growth
- GMM N/A
- PDSB N/A
- EPS
- GMM 1.79
- PDSB N/A
- Revenue
- GMM $48,171,048.00
- PDSB N/A
- Revenue This Year
- GMM N/A
- PDSB N/A
- Revenue Next Year
- GMM N/A
- PDSB N/A
- P/E Ratio
- GMM $1.10
- PDSB N/A
- Revenue Growth
- GMM 41.74
- PDSB N/A
- 52 Week Low
- GMM $1.69
- PDSB $0.85
- 52 Week High
- GMM $15.60
- PDSB $4.29
- Technical
- Relative Strength Index (RSI)
- GMM 39.06
- PDSB 44.36
- Support Level
- GMM $1.86
- PDSB $1.12
- Resistance Level
- GMM $2.09
- PDSB $1.26
- Average True Range (ATR)
- GMM 0.21
- PDSB 0.08
- MACD
- GMM -0.01
- PDSB -0.01
- Stochastic Oscillator
- GMM 12.36
- PDSB 15.79
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.